BioNexus Gene Lab Corp BGLC 深 沪
等待开盘 02-05 09:30:00 美东时间
2.40
-0.250
-9.43%
华盛通- 最 高2.50
- 今 开2.47
- 成交量 3.89万股
- 最 低 2.37
- 昨 收 2.65
- 总市值 431.18万
- 52周最高 15.60
- 市盈率 静 --
- 换手率 2.16%
- 52周最低 2.0068
- 委 比 44.44%
- 总股本 179.66万
- 历史最高 94.90
- 量 比 0.46
- 振 幅 4.91%
- 历史最低 2.105
- 每 手 1
- 风险率 1.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioNexus Gene Lab Commences Its 2026 Deployment Phase For VitaGuard Minimal Residual Disease Platform
BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company"), a technology-driven precision diagnostics company, today announced the formal commencement of its 2026 Deployment Phase for the VitaGuard™
01-28 22:01
BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market
BioNexus Gene Lab Corp (BGLC) announced the commencement of its 2026 Deployment Phase for the VitaGuard™ Minimal Residual Disease (MRD) platform, aiming to make cancer monitoring more accessible and affordable across Southeast Asia. The platform is designed to disrupt high-cost legacy systems by targeting a cost profile below $3,000 per test. BGLC CEO Sam Tan emphasized the company's focus on regional strength and sustainable market capture, leve...
01-28 14:00
BioNexus Gene Lab Executes Intellectual Property License Agreement For Southeast Asia With Fidelion Diagnostics For VitaGuard Minimal Residual Disease Liquid Biopsy Platform
BioNexus Gene Lab Corp. ("BGLC") today announced that it has executed an Exclusive Intellectual Property License Agreement for Southeast Asia with Fidelion Diagnostics Pte. Ltd. ("Fidelion") for the VitaGuard™
2025-12-01 21:07
12 Industrials Stocks Moving In Monday's Pre-Market Session
Gainers FGI Industries (NASDAQ:FGI) shares rose 35.8% to $6.46 during Monday's...
2025-10-20 20:08
BioNexus Gene Enters Partnership With BirchBioMed To Lead Birch's $10M Funding Round Through Equity Investment, Collaboration
BioNexus Gene Lab Corp (NASDAQ:BGLC, "BGLC", or the "Company")), today announced that it has entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. ("Birch"), a Canadian biopharmaceutical
2025-10-20 20:01
BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.
BGLC and BirchBioMed have entered into a non-binding strategic partnership to commercialize Birch's FS2 topical platform in Southeast Asia. BGLC will lead a USD $10 million financing round for Birch and provide market and regulatory support in Malaysia and Singapore. BGLC will receive 1.5 million Birch shares in exchange for a 4.99% stake. Both companies aim to leverage their respective strengths to advance innovative skin treatments in the regio...
2025-10-20 12:00
12 Industrials Stocks Moving In Wednesday's Intraday Session
Gainers BioNexus Gene Lab (NASDAQ:BGLC) shares moved upwards by 39.9% to $6.24...
2025-07-31 01:07
BioNexus Gene Lab shares are trading higher after the company announced it will acquire an equity stake in Fielion and secure exclusive commercial rights to VitaGaurd across Southeast Asia.
BioNexus Gene Lab shares are trading higher after the company announced it will...
2025-07-30 23:53
BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology
BioNexus Gene Lab Corp. (BGLC) and Fidelion Diagnostics have entered a strategic partnership to commercialize Fidelion's VitaGuard liquid biopsy platform in Southeast Asia. VitaGuard, developed by China's Tongshu Gene, enables cost-effective, tumor-naïve cancer monitoring with high sensitivity (0.02% variant-allele-frequency) at under USD $300 per test. The partnership aims to leverage BGLC's commercial network to expand access to advanced cancer...
2025-07-30 12:00
